Alunbrig (brigatinib) — Medica
Inflammatory Myofibroblastic Tumor (IMT)
Initial criteria
- Patient is age ≥ 18 years
- Patient has anaplastic lymphoma kinase (ALK)-positive disease
- Patient meets ONE of the following: advanced, recurrent, or metastatic disease OR the tumor is inoperable
Approval duration
1 year